Pharmaceutical

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Melanoma: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Melanoma.

Apr 19, 2024 - 00:00
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Melanoma.
Read the original article

Tags:

Previous Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Hodgkin Lymphoma: Li...

Next Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Cervical Cancer: Likelih...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Scottish company secures £4.2m to advance 3D-printed micro-tumour tech

Scottish company secures £4.2m to advance 3D-printed mi...

Feb 2, 2024

Which biotechs need to find a new bank after the collapse of Silicon Valley Bank?

Which biotechs need to find a new bank after the collap...

Mar 19, 2023

STAT+: Wyden decries ‘astonishingly low’ tax rates for pharma companies as he probes business maneuvers

STAT+: Wyden decries ‘astonishingly low’ tax rates for ...

May 11, 2023